Paul Sabbatini

20.8k total citations · 3 hit papers
182 papers, 8.8k citations indexed

About

Paul Sabbatini is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Paul Sabbatini has authored 182 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Reproductive Medicine, 65 papers in Oncology and 44 papers in Surgery. Recurrent topics in Paul Sabbatini's work include Ovarian cancer diagnosis and treatment (96 papers), Intraperitoneal and Appendiceal Malignancies (42 papers) and Endometrial and Cervical Cancer Treatments (27 papers). Paul Sabbatini is often cited by papers focused on Ovarian cancer diagnosis and treatment (96 papers), Intraperitoneal and Appendiceal Malignancies (42 papers) and Endometrial and Cervical Cancer Treatments (27 papers). Paul Sabbatini collaborates with scholars based in United States, Japan and South Korea. Paul Sabbatini's co-authors include Carol Aghajanian, David R. Spriggs, Martee L. Hensley, Richard R. Barakat, Howard I. Scher, Deborah Schrag, Dorothy Dulko, Ethan Basch, Clifford A. Hudis and Jakob Dupont and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Paul Sabbatini

176 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

2015 1.7k citations Clifford A. Hudis, Paul Sabbatini et al. Journal of Clinical Oncology profile →
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

2002 498 citations Martee L. Hensley, Ennapadam Venkatraman et al. Journal of Clinical Oncology profile →
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

2017 406 citations Robert L. Coleman, Mark F. Brady et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Sabbatini United States	45	4.0k	2.5k	1.9k	1.8k	1.5k	182	8.8k
R. Kreienberg Germany	54	4.3k 1.1×	1.5k 0.6×	1.3k 0.7×	2.1k 1.2×	1.3k 0.9×	434	10.6k
Mark F. Munsell United States	64	3.6k 0.9×	1.6k 0.6×	2.2k 1.2×	2.0k 1.1×	2.8k 1.9×	243	11.8k
Clemens Tempfer Austria	52	1.9k 0.5×	2.6k 1.0×	796 0.4×	1.9k 1.0×	2.1k 1.4×	374	9.2k
Timothy Perren United Kingdom	42	3.0k 0.8×	2.2k 0.9×	902 0.5×	1.4k 0.8×	1.3k 0.9×	151	6.6k
Diane C. Bodurka United States	54	3.4k 0.9×	3.9k 1.5×	1.1k 0.6×	1.2k 0.7×	2.5k 1.7×	210	10.7k
Martee L. Hensley United States	55	4.2k 1.0×	3.8k 1.5×	4.7k 2.5×	1.8k 1.0×	1.6k 1.1×	223	13.3k
Barbara A. Goff United States	57	2.4k 0.6×	5.4k 2.1×	1.1k 0.6×	1.4k 0.8×	2.6k 1.8×	231	10.2k
Mark A. Morgan United States	45	1.4k 0.4×	1.8k 0.7×	844 0.4×	1.1k 0.6×	1.7k 1.2×	201	6.8k
Noriyuki Katsumata Japan	38	2.8k 0.7×	1.3k 0.5×	811 0.4×	776 0.4×	1.2k 0.8×	183	5.7k
Linda Mileshkin Australia	40	3.2k 0.8×	1.2k 0.5×	938 0.5×	1.6k 0.9×	558 0.4×	273	6.6k

Countries citing papers authored by Paul Sabbatini

Since Specialization

Citations

This map shows the geographic impact of Paul Sabbatini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Sabbatini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Sabbatini more than expected).

Fields of papers citing papers by Paul Sabbatini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Sabbatini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Sabbatini. The network helps show where Paul Sabbatini may publish in the future.

Co-authorship network of co-authors of Paul Sabbatini

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Sabbatini. A scholar is included among the top collaborators of Paul Sabbatini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Sabbatini. Paul Sabbatini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johannet, Paul, M. Herman Chui, Jason Konner, et al.. (2025). Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate. Gynecologic Oncology. 195. 173–179.

Buckley, Michael, et al.. (2023). Integrating technology to support data management abstraction of adverse events (AE) and concomitant medications (ConMed) from the electronic health record (EHR) to sponsor electronic data capture (EDC) systems using design thinking (DT) methodology.. Journal of Clinical Oncology. 41(16_suppl). e13624–e13624.

Manning‐Geist, Beryl, Sacha Gnjatic, Carol Aghajanian, et al.. (2023). Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers. 15(5). 1458–1458. 12 indexed citations

O’Cearbhaill, Roisin E., Sacha Gnjatic, Carol Aghajanian, et al.. (2018). A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. Journal of Clinical Oncology. 36(15_suppl). 5553–5553. 6 indexed citations

Coleman, Robert L., Mark F. Brady, Thomas J. Herzog, et al.. (2015). A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Gynecologic Oncology. 137. 3–4. 31 indexed citations

Tsuji, Takemasa, Paul Sabbatini, Achim A. Jungbluth, et al.. (2013). Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial. Cancer Immunology Research. 1(5). 340–350. 52 indexed citations

Kaye, Stanley B., Louis Fehrenbacher, Robert W. Holloway, et al.. (2012). A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission. Clinical Cancer Research. 18(23). 6509–6518. 102 indexed citations

Barlin, Joyce N., Fanny Dao, Sarah E. Ferguson, et al.. (2012). Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin is comparable to results from GOG 172. Gynecologic Oncology. 125. S36–S37. 1 indexed citations

Konner, Jason, Scott R. Gerst, Alexia Iasonos, et al.. (2011). Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer. Journal of Clinical Oncology. 29(35). 4662–4668. 44 indexed citations

10.

Kauff, Noah D., Susan M. Domchek, Tara M. Friebel, et al.. (2008). Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. Journal of Clinical Oncology. 26(8). 1331–1337. 381 indexed citations

11.

Konner, Jason, Alexia Iasonos, Paul Sabbatini, et al.. (2007). A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. Journal of Clinical Oncology. 25(18_suppl). 5523–5523. 15 indexed citations

12.

Hensley, Martee L., Denise D. Correa, Howard T. Thaler, et al.. (2006). Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecologic Oncology. 102(2). 270–277. 25 indexed citations

13.

Maluf, Fernando Cotait, Aliza Leiser, Carol Aghajanian, et al.. (2006). Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. International Journal of Gynecological Cancer. 16(3). 1165–1171. 27 indexed citations

14.

McMeekin, D. Scott, Alan N. Gordon, Jeffrey M. Fowler, et al.. (2003). A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecologic Oncology. 90(1). 64–69. 55 indexed citations

15.

Leitão, Mario M., Amanda Hummer, Don S. Dizon, et al.. (2003). Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecologic Oncology. 91(1). 123–129. 36 indexed citations

16.

Dizon, Don S., Paul Sabbatini, Carol Aghajanian, Martee L. Hensley, & David R. Spriggs. (2002). Analysis of Patients with Epithelial Ovarian Cancer or Fallopian Tube Carcinoma Retreated with Cisplatin after the Development of a Carboplatin Allergy. Gynecologic Oncology. 84(3). 378–382. 91 indexed citations

17.

Dennis, S. & Paul Sabbatini. (2000). Advanced ovarian cancer. Current Treatment Options in Oncology. 1(2). 139–146. 27 indexed citations

18.

Sabbatini, Paul. (2000). The Relationship between Anemia and Quality of Life in Cancer Patients. The Oncologist. 5(90002). 19–23. 3 indexed citations

19.

Sabbatini, Paul. (2000). Contribution of anemia to fatigue in the cancer patient.. PubMed. 14(11A). 69–71. 7 indexed citations

20.

Sabbatini, Paul. (2000). The Relationship between Anemia and Quality of Life in Cancer Patients. The Oncologist. 5(S2). 19–23. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact